A breakthrough has occurred in the laboratory at the University of Bonn that could redefine the future of regenerative medicine: researchers took blood cells from an 80-year-old person and reversed their molecular aging by more than 60 years.
The essence of the method lies in reprogramming immature blood cells into neural stem cells, from which brain cells subsequently form. To assess the result, the scientists used "epigenetic clocks" — markers of chemical changes in DNA associated with aging. The readings recorded a radical rejuvenation of cellular age.
Bypassing the intermediate phase
Previously, a rapid reduction in cellular age was achieved only through an intermediate stage of pluripotent stem cells. The approach developed in Bonn made it possible to bypass this stage, which enabled observation of gradual rejuvenation in real time over more than 100 days.
This method opens the way to identifying substances that accelerate or slow the aging process — critically important for understanding diseases where age is a key risk factor, including Alzheimer's disease. At the same time, the experiment has not yet confirmed that the scheme can safely treat diseases in humans.
First trials on patients
In January, US regulators allowed the company Life Biosciences to test the drug ER-100 — an experimental agent for restoring damaged eye cells. Three patients with glaucoma received the drug for 56 days, and two of them showed preliminary improvement in vision test results. The data published on October 8 are so far limited to a small uncontrolled safety sample.
A multi-billion-dollar race for youth
Investors are pouring enormous funds into research on preserving youth. In 2025, the longevity biotechnology sector attracted a record $18.4 billion versus $4.7 billion a year earlier, and by mid-September 2026 another $12.1 billion had been invested.
The startup NewLimit, founded by Coinbase creator Brian Armstrong, raised $435 million in June with participation from Eli Lilly Ventures and plans to begin trials of a therapy against aging liver cells in 2027. Retro Biosciences, backed by Sam Altman of OpenAI, reached a valuation of $1.8 billion and is already testing an experimental pill for Alzheimer's disease. Altos Labs has raised $3 billion for cell rejuvenation technology, and VitaDAO, funded through crypto assets, has supported more than 30 projects in the field of longevity.
Cryptalist analysis: The longevity sector is demonstrating explosive growth in capitalization and is attracting capital from the crypto industry through decentralized financing mechanisms, which is forming a new asset class at the intersection of biotech and Web3. However, the industry's fundamental problem remains unchanged — the gap between laboratory achievements and proven clinical efficacy in humans, and it is precisely this gap that will determine the real valuation of companies in the coming years.